Evaluation of the role of kefir in management of non-alcoholic steatohepatitis rat model via modulation of NASH linked mRNA-miRNA panel

• Published in: Scientific reports Vol. 13; no. 1; p. 236
• Main Authors: Salah, Noha, Eissa, Sanaa, Mansour, Amal, El Magd, Nagwa M. Abo, Hasanin, Amany Helmy, El Mahdy, Manal M., Hassan, Mohamed Kamel, Matboli, Marwa
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 05.01.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/337; 692/4017; 692/4020; Animals; Biochemistry; Bioinformatics; Biomarkers; Cholesterol; Diet; Diet, High-Fat - adverse effects; Disease Models, Animal; Drug dosages; Epigenetics; Fatty liver; Fibrosis; Genomics; High density lipoprotein; High fat diet; Humanities and Social Sciences; Inflammation; Interleukin-6 - metabolism; Kefir; Lipids; Liver - metabolism; Liver diseases; Medicine; Microbiota; MicroRNAs; MicroRNAs - metabolism; miRNA; mRNA; multidisciplinary; Non-alcoholic Fatty Liver Disease - genetics; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - therapy; Probiotics; Rats; Science; Science (multidisciplinary); Smad4 protein; Steatosis; Sucrose; Transforming growth factor-b1
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-27353-x

Non-alcoholic steatohepatitis (NASH) is the clinically aggressive variant of non-alcoholic fatty liver disease. Hippo pathway dysregulation can contribute to NASH development and progression. The use of probiotics is effective in NASH management. Our aim is to investigate the efficacy of kefir Milk in NASH management via modulation of hepatic mRNA-miRNA based panel linked to NAFLD/NASH Hippo signaling and gut microbita regulated genes which was identified using bioinformatics tools. Firstly, we analyzed mRNAs (SOX11, SMAD4 and AMOTL2), and their epigenetic regulator (miR-6807) followed by validation of target effector proteins (TGFB1, IL6 and HepPar1). Molecular, biochemical, and histopathological, analyses were used to evaluate the effects of kefir on high sucrose high fat (HSHF) diet -induced NASH in rats. We found that administration of Kefir proved to prevent steatosis and development of the inflammatory component of NASH. Moreover, Kefir improved liver function and lipid panel. At the molecular level, kefir down-regulated the expression of miR 6807-5p with subsequent increase in the expression of SOX 11, AMOTL2 associated with downregulated SMAD4, resulting in reduction in the expression of the inflammatory and fibrotic markers, IL6 and TGF-β1 in the treated and prophylactic groups compared to the untreated rats. In conclusion, Kefir suppressed NASH progression and improved both fibrosis and hepatic inflammation. The produced effect was correlated with modulation of SOX11, SMAD4 and AMOTL2 mRNAs) – (miR-6807-5p) – (TGFB, IL6 and, HepPar1) expression.